Last reviewed · How we verify
Betamethasone-17,21-dipropionate
Betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors.
Betamethasone dipropionate is a potent topical corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids, Eczema, psoriasis, and other chronic inflammatory skin conditions.
At a glance
| Generic name | Betamethasone-17,21-dipropionate |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
This synthetic corticosteroid works by penetrating skin tissue and binding to intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory responses. The dipropionate ester formulation enhances skin penetration and potency compared to the parent betamethasone molecule.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids
- Eczema, psoriasis, and other chronic inflammatory skin conditions
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local skin irritation
- Folliculitis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Betamethasone-17,21-dipropionate CI brief — competitive landscape report
- Betamethasone-17,21-dipropionate updates RSS · CI watch RSS
- LEO Pharma portfolio CI